The design and results of the aristotle trial have been published previously. However, because bleeding events which are associated with a low dose 110 mg versus a high dose 150 mg of dabigatran have seldom been compared, we aimed to systematically solve this important issue. Dabigatran for stroke prevention in atrial fibrillation. Rivaroxaban oncedaily, oral, direct factor xa inhibition compared with vitamin k. Randomized evaluation of longterm anticoagulant therapy, warfarin, compared with dabigatran author links open overlay panel michael d. Safety and efficacy of dabigatran etexilate vs doseadjusted. Dabigatran increases the risk of hemorrhage and may cause serious, sometimes fatal bleeding. Efficacy and safety of dabigatran versus warfarin from the. Dabigatran was compared to warfarin in the randomized evaluation of longterm anticoagulation therapy rely trial, an open label comparison of dabigatran 110 mg bid or 150 mg bid in a blinded fashion and adjusteddose warfarin in 18,1 patients over a median followup period of 2. Fda approves pradaxa, marking a major milestone to reduce the risk of stroke in patients with nonvalvular atrial fibrillation. The rely trial randomized evaluation of longterm anticoagulant therapy compared dabigatran 150 and 110 mg twice daily with warfarin in 18 1 patients with atrial fibrillation.
Reilly phd c jeanne varrone md c susan wang phd c jonas oldgren md, phd d ellison themeles b. Dabigatran functions as a direct thrombin inhibitor. Ezekowitz md1, connolly s, parekh a, reilly pa, varrone j, wang s, oldgren j, themeles e, wallentin l, yusuf s. Methods plasma samples were obtained at randomisation and after 3 months in 2514 patients with af in the rely trial. Pharmaceutical benefits scheme pbs apixaban, tablet, 2. Reilly and jeanne varrone and susan wang and jonas. Risk factors included being 75 years or older and having hypertension. Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease. Dabigatran, rivaraoxaban, and apixaban are new oral.
Fda approves pradaxa, marking a major milestone to reduce the. Postmarketing surveillance and the ongoing dabigatran controversy background. Dabigatran compared with warfarin in patients with atrial. Objectives to evaluate the prognostic importance of transient or persistent elevations of cardiac troponini ctni and nterminalbtype natriuretic peptide ntprobnp in atrial fibrillation af. All authors vouch for the accuracy and completeness of the data. We evaluated the effects of dabigatran compared with warfarin in the subgroup of patients with previous symptomatic heart failure hf in the re. Among patients weighing less than 50 kg, there was a 1. Ezekowitz md, connolly s, parekh a, reilly pa, varrone j, wang s, oldgren j, themeles e, wallentin l, yusuf s. Patients were enrolled in rely from december 2005 to december 2007. A single institutions experience with using dabigatran, rivaroxaban and warfarin for prevention of thromboembolism in atrial fibrillation. The trial design, patient characteristics and outcomes of the rely study have been published previously. Combined anticoagulantantiplatelet use and major bleeding events in elderly atrial fibrillation patients. Dec, 2010 pdf efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation. Dabigatran versus warfarin for stroke prevention in.
Ezekowitz md, connolly s, parekh a, reilly pa, varrone j, wang s, et al. Review article dabigatran, rivaroxaban, or apixaban versus. Ly trial, european journal of heart failure on deepdyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips. Ly trial were analyzed for dabigatran exposure by body weight. Hospital of cook county, department of internal medicine, chicago, il. Concomitant oral anticoagulant and nonsteroidal anti. The rationale and design of the rely trial, as well as its primary outcomes were previously described. The study organization, trial design, patient characteristics, and outcomes of the re.
The rely trial is a landmark study with regard to the manage. Apixaban is a novel oral direct factor xa inhibitor that. A promising new anticoagulant for stroke prevention. The openlabel study involved 120 patients from nine countries and looked to evaluate the suitability of dabigatran etexilate and warfarin for the treatment and secondary. Cardiac biomarkers and left ventricular hypertrophy in. The newer oral anticoagulant dabigatran is considered to be more beneficial in patients with nonvalvular atrial fibrillation af when compared to warfarin. Comparison of dabigatran and warfarin in patients with.
The use of dabigatran in general practice bpj issue 38. Respect cvt was a prospective, randomised exploratory study assessing the safety and efficacy of dabigatran etexilate and warfarin in patients who suffer from cvt. Dabigatran versus warfarin in patients with atrial. Dabigatran versus warfarin for stroke prevention in patients with atrial fibrillation. For all vascular events, nonhaemorrhagic events, and mortality, advantages of dabigatran were greater at sites with poor inr control than at those with good inr control. A full description of the inclusion and exclusion criteria applied is. Demonstrated to significantly reduce stroke compared to warfarin, pradaxa is first new oral anticoagulant approved by the fda in more than 50 years.
Objectives the goal of this study was to analyze the impact of dabigatran plasma concentrations, patient demographics, and aspirin asa use on frequencies of ischemic strokessystemic emboli and major bleeds in atrial fibrillation patients. In this noninferiority trial, we randomly assigned 18,1 patients who had. Postmarketing surveillance and the ongoing dabigatran. Inclusion criteria were documented af and at least one. Comparison of bleeding risk scores in patients with atrial. Efficacy and safety of dabigatran versus warfarin from the rely trial. Randomized evaluation of longterm anticoagulant therapy, warfarin, compared with dabigatran article in american heart journal 1575. We would like to address a number of questions with regard to the interpretation of this landmark trial comparing the efficacy of two dosages blinded of the selective thrombin inhibitor, dabigatran, to adjusted warfarin unblinded to.
Dyspepsia is a commonly reported adverse effect with dabigatran. Publications home of jama and the specialty journals of. Patients continued into rely able beginning at their final rely visit. Safety and efficacy of dabigatran etexilate vs dose. Rely and its substudies to date posted by beverly murphy monday, december, 2010 according to the american heart association, atrial fibrillation af is estimated to affect more than 2. Ezekowitz md1, connolly s, parekh a, reilly pa, varrone j, wang s. However, there is a paucity of data on the antithrombotic efficacy and safety of dabigatran in the resolution of left atrial appendage laa thrombi in af patients.
Rationale and design of the related afafnet 7 trial. Rationale, design, and protocol of a randomized controlled trial of the safety and efficacy of dabigatran etexilate versus doseadjusted warfarin in patients with cerebral venous thrombosis. Connolly sj, ezekowitz md, yusuf s, reilly pa, wallentin l. Reilly phd c jeanne varrone md c susan wang phd c jonas oldgren md. Dabigatran etexilate, a direct thrombin inhibitor and nonvitamin k antagonist oral anticoagulant noac, has been shown to effectively prevent thromboembolic events in patients with nonvalvular atrial fibrillation af. Clinical outcome event rates within 30 days postcardioversion in rely,7 aristotle,10 and rocketaf11 studies rely dabigatran 150 mg rely dabigatran 110 mg rely warfarin aristotle apixaban aristotle warfarin rocketaf. What are the emerging therapeutic alternatives to warfarin. Representativeness of the dabigatran, apixaban and. A prospective, randomized, phase 3b study comparing the safety and efficacy of dual antithrombotic therapy with dabigatran etexilate versus warfarin. Rely is a phase 3, multicenter, prospective, openlabel, randomized trial with blinded evaluation of all outcomes probe design. The rationale, design, and protocol of respect cvt have been published previously 17. The key findings of this analysis of rely are the following. For all vascular events, nonhaemorrhagic events, and mortality, advantages of dabigatran were greater at sites with poor inr control than at those with good.
Randomised evaluation of long term anticoagulant therapy, warfarin compared with dabigatran. Wallentin l, yusuf s, ezekowitz md, alings m, flather m, franzosi mg, pais p, dans a, eikelboom j, oldgren j, pogue j, reilly pa, yang s. Background the efficacy and safety of dabigatran etexilate were demonstrated in the rely randomized evaluation of. Dabigatran versus warfarin in patients with atrial fibrillation nejm. What are the emerging therapeutic alternatives to warfarin in stroke patients. Randomized evaluation of long term anticoagulation therapy. Read dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure. The rely study 8 is a trial of 18 000 patients with atrial fibrillation who were randomized between warfarin or one of two doses of dabigatran etexilate 110 mg b. We would like to respond to the esc hotline commentary by john camm 1 discussing the results of the rely study 2.
Detailed descriptions of the rationale and design of the rely trial have been published previously. The effect of dabigatran plasma concentrations and patient. Randomized evaluation of longterm anticoagulation therapy, warfarin, compared with dabigatran. As demonstrated in the rely trial, pradaxa 150mg taken twice daily has been shown to significantly reduce stroke and systemic embolism by 35 percent beyond the reduction achieved with warfarin, 1 the current standard of care for patients with nonvalvular atrial fibrillation. Fda approves pradaxa, marking a major milestone to reduce. Apixaban compared with parenteral heparin andor vitamin k.
The rely trial randomized evaluation of longterm anticoagulant. Ly trial enrolled 18 1 patients with nonvalvular af who were randomized to receive oac therapy with dabigatran 110 mg bid, dabigatran 150 mg bid or dose. John camm st georges university of london, london, uk. A total of 18 1 patients with af, with at least 1 additional risk factor for stroke, were. A prospective, randomized, phase 3b study comparing the safety and efficacy of dual antithrombotic therapy with dabigatran etexilate versus warfarin triple therapy in patients with nonvalvular atrial fibrillation who have undergone percutaneous coronary intervention with stenting. However, there is a paucity of data on the antithrombotic efficacy and safety of dabigatran in the resolution of left atrial appendage laa thrombi in af. It is administered in a fixed dose without laboratory monitoring and is being compared with warfarin international normalized ratio 23 in the rely trial. These results are largely consistent with that from rely and rocketaf, which showed that both dabigatran dosed at 110mg twice daily and rivaroxaban had comparable stroke risk to warfarin. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation. Publications home of jama and the specialty journals of the.
The appropriate regulatory authorities and ethics committees approved the study. The final rely study visits occurred between december 2008 and march 2009. Jun 25, 2015 dabigatran etexilate, a direct thrombin inhibitor and nonvitamin k antagonist oral anticoagulant noac, has been shown to effectively prevent thromboembolic events in patients with nonvalvular atrial fibrillation af. Apixaban, dabigatran, and rivaroxaban for atrial fibrillation. Pradaxa dabigatran etexilate, 150mg bid shows significant. Dabigatran etexilate is absorbed after oral administration of dabigatran etexilate mesylate and hydrolyzed to the active moiety, dabigatran, by esterases in plasma and the liver. Two doses of dabigatran are compared with warfarin for stroke prevention in patients with nvaf and at least 1 risk factor for stroke. Bleeding events associated with a low dose 110 mg versus. Oct 16, 2017 details about the study design and main results have been reported elsewhere 16, 17. The pharmacology and therapeutic use of dabigatran. Details about the study design and main results have been reported elsewhere 16, 17. The effects of 110 mg dabigatran and 150 mg dabigatran twice daily in patients with previous stroke or transient ischaemic attack are consistent with those of other patients in rely, for whom, compared with warfarin, 150 mg dabigatran reduced stroke or systemic embolism and 110 mg dabigatran was noninferior. Randomized evaluation of longterm anticoagulant therapy, warfarin, compared with dabigatran. Stroke is the leading cause of morbidity and mortality in patients with atrial fibrillation.
Reilly phd c jeanne varrone md c susan wang phd c jonas oldgren md, phd d ellison themeles b lars wallentin. We recruited consecutive patients of either sex who were between 18 and 79 years of age and had a diagnosis of cvt confirmed by magnetic resonance imaging mri plus mr venography, computed tomography ct. What are the emerging therapeutic alternatives to warfarin in. The design and results of the rely study have been previously published. Ezekowitz mbchb, dphil a stuart connolly md b amit parekh md a paul a. Jan 22, 2019 ezekowitz md, connolly s, parekh a, reilly pa, varrone j, wang s, oldgren j, themeles e, wallentin l, yusuf s. Half the patients had no previous exposure to warfarin treatment.
Ly compared two fixed and blinded doses of dabigatran 110 and 150 mg twice daily with open. Efficacy and safety of dabigatran versus warfarin from the re. Rely able visits occurred at 4, 8, 18, and 23 months. The randomized evaluation of longterm anticoagulation therapy rely trial allowed patients who completed the trial receiving their assigned dabigatran 150 mg d150 or 110 mg d110 twice a day to continue into the longterm multicenter extension of dabigatran treatment in patients with atrial fibrillation rely able trial. Comparison of dabigatran and warfarin in patients with atrial. The trial design was prospective, randomized, and open, with blinded. Apixaban versus warfarin in patients with atrial fibrillation. Fda approves boehringer ingelheim pharmaceuticals, inc. In addition, women showed a 30% higher predose and postdose dabigatran concentration than men. The inclusionexclusion criteria from rely, rocketaf and aristotle were derived primarily from the trial design and rationale publications,2224 with clarification sought from supplementary appendices and primary clinical trial result publications 79 where required. The benefits of 150 mg dabigatran at reducing stroke, 110 mg dabigatran at reducing bleeding, and both doses at reducing intracranial bleeding versus warfarin were consistent irrespective of centres quality of inr control. Sep 01, 20 read dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure. Pdf appraisal of noninferiority margins in assessing study quality.
953 691 1286 955 1499 1280 1007 447 444 784 159 1005 113 78 1460 1527 1494 1021 578 1187 66 114 38 738 1364 1001 919 1254 310 1045 1188 286 1184 36 97 65 499 1502 1165 575 1131 201 1051 306 1412 1247 314